



STATE OF HAWAII
DEPARTMENT OF HUMAN SERVICES

Med-QUEST Division
Clinical Standards Office
P. O. Box 700190
Kapolei, Hawaii 96709-0190

October 7, 2021

MEMORANDUM

MEMO NO.

QI-2126A

FFS 21-11A

TO: Federally Qualified Health Centers /Rural Health Centers (FQHCs/RHCs)
QUEST Integration (QI) Health Plans

FROM: Judy Mohr Peterson, PhD *JMP*
Med-QUEST Division Administrator

SUBJECT: COVID-19 MONOCLONAL ANTIBODY TREATMENT – FQHC/RHC
REIMBURSEMENT FOR ADMINISTRATION

This memo replaces QI-2126 and FFS 21-11 issued on September 30, 2021. The administration fee allowance and effective dates were changed to reflect and align with Hawaii adjusted Medicare rates.

This memorandum is being issued as Federally Qualified Health Centers/Rural Health Centers (FQHCs/RHCs) are now one of the providers who are able to receive reimbursement for the administration of COVID-19 Monoclonal Antibody products.

In our assessment, the cost to provide monoclonal treatments is not currently included in FQHC/RHC Prospective Payment System (PPS) rate calculation. Therefore, FQHCs/RHCs that administer monoclonal infusion therapy or by injection are to be reimbursed at the fee-for-service (FFS) rather than their PPS rate.

The administration of monoclonal antibodies must be in accordance with current [FDA guidelines](#). Details on reimbursement of the administration fee in terms of codes, rates, and effective dates are outlined below. The FQHC/RHC should bill only the FFS administration fee for the monoclonal

therapy and will not be eligible for PPS on the same day unless it is for an issue unrelated to the administration of the monoclonal therapy.

HCPCS Code	HCPCS Short Descriptor	Administration Fee Allowance	Effective Date
M0243	Casirivi and imdevi inj	\$ 505.74	05/06/21
M0244	Casirivi and imdevi inj hm	\$ 843.38	05/06/21
M0240	Casirivi and imdev repeat	\$ 505.74	05/06/21
M0241	Casiri and imdev repeat hm	\$ 843.38	05/06/21
M0245	Bamlan and etesev infusion	\$ 505.74	05/06/21
M0246	Bamlan and etesev infus home	\$ 843.38	05/06/21

This policy supports MQD's continued COVID-19 public health emergency response and recovery efforts to provide timely care with improved outcomes, increase access to care in our beneficiary's communities, and decrease hospitalization.

Should you have questions please contact Leslie K. Tawata, Clinical Standards Office Administrator at ltawata@dhs.hawaii.gov.

References:

- 1) FDA: Drugs. <https://www.fda.gov/drugs>
- 2) CMS: COVID-19 Vaccines and Monoclonal Antibodies, modified 9/27/21. [COVID-19 Vaccines and Monoclonal Antibodies](#)